Achromobacter xylosoxidans in cystic fibrosis: prevalence and clinical relevance.
about
Complete genome sequence of the cystic fibrosis pathogen Achromobacter xylosoxidans NH44784-1996 complies with important pathogenic phenotypesGenotypic and phenotypic applications for the differentiation and species-level identification of achromobacter for clinical diagnoses.Measuring and improving respiratory outcomes in cystic fibrosis lung disease: opportunities and challenges to therapyAchromobacter xylosoxidans genomic characterization and correlation of randomly amplified polymorphic DNA profiles with relevant clinical features [corrected] of cystic fibrosis patients.The development of lower respiratory tract microbiome in miceThe changing microbial epidemiology in cystic fibrosis.Mutations that permit residual CFTR function delay acquisition of multiple respiratory pathogens in CF patients.Clinical significance of microbial infection and adaptation in cystic fibrosis.Improved characterization of medically relevant fungi in the human respiratory tract using next-generation sequencing.Low rates of Pseudomonas aeruginosa misidentification in isolates from cystic fibrosis patients.Achromobacter xylosoxidans: characterization of strains in Brazilian cystic fibrosis patientsThe Microbiome in Cystic Fibrosis.Assessment of the Microbial Constituents of the Home Environment of Individuals with Cystic Fibrosis (CF) and Their Association with Lower Airways Infections.Epidemic Achromobacter xylosoxidans strain among Belgian cystic fibrosis patients and review of literature.Clinical impact of Achromobacter xylosoxidans colonization/infection in patients with cystic fibrosis.Hospital Acquired Pneumonia Due to Achromobacter spp. in a Geriatric Ward in China: Clinical Characteristic, Genome Variability, Biofilm Production, Antibiotic Resistance and Integron in Isolated Strains.Comparing the harmful effects of nontuberculous mycobacteria and Gram negative bacteria on lung function in patients with cystic fibrosisPulmonary bacterial pathogens in cystic fibrosis patients and antibiotic therapy: a tool for the health workers.Molecular characterization of Achromobacter isolates from cystic fibrosis and non-cystic fibrosis patients in Madrid, Spain.Sepsis Caused by Achromobacter Xylosoxidans in a Child with Cystic Fibrosis and Severe Lung Disease.Update on antibiotics for infection control in cystic fibrosis.Sputum DNA sequencing in cystic fibrosis: non-invasive access to the lung microbiome and to pathogen details.Current dilemmas in antimicrobial therapy in cystic fibrosis.Genome Sequencing Reveals the Potential of Achromobacter sp. HZ01 for Bioremediation.Update on host-pathogen interactions in cystic fibrosis lung disease.First description of an RND-type multidrug efflux pump in Achromobacter xylosoxidans, AxyABM.A Different Microbiome Gene Repertoire in the Airways of Cystic Fibrosis Patients with Severe Lung Disease.Infection in cystic fibrosis: impact of the environment and climate.Clinical Features, Antibiotic Susceptibility Profiles, and Outcomes of Infectious Keratitis Caused by Achromobacter xylosoxidans.Prevalence and Outcomes of Achromobacter Species Infections in Adults with Cystic Fibrosis: a North American Cohort Study.Clinical Outcomes Associated with Achromobacter Species Infection in Patients with Cystic Fibrosis.Patterns of virulence factor expression and antimicrobial resistance in Achromobacter xylosoxidans and Achromobacter ruhlandii isolates from patients with cystic fibrosis.Effect of High-Dose Antimicrobials on Biofilm Growth of Achromobacter Species Isolated from Cystic Fibrosis Patients.In Vitro Activity of Ceftolozane-Tazobactam against Multidrug-Resistant Nonfermenting Gram-Negative Bacilli Isolated from Patients with Cystic Fibrosis.Detection of Achromobacter xylosoxidans in hospital, domestic, and outdoor environmental samples and comparison with human clinical isolates.Prevalence of Achromobacter xylosoxidans in pulmonary mucosa-associated lymphoid tissue lymphoma in different regions of Europe.Innate aminoglycoside resistance of Achromobacter xylosoxidans is due to AxyXY-OprZ, an RND-type multidrug efflux pump.Achromobacter xylosoxidans induced bronchiolitis obliterans in cystic fibrosis.Bacterial infections in patients with primary ciliary dyskinesia: Comparison with cystic fibrosis.An orphan cbb3-type cytochrome oxidase subunit supports Pseudomonas aeruginosa biofilm growth and virulence.
P2860
Q21132701-F3ECABCA-BD4E-494E-954A-5E94780613F8Q30874298-D47C101D-CAB7-4E8E-9B1C-EBEFB20C5544Q33697276-A5F69571-ECCB-4DB7-AE2D-424A244A4E69Q33769610-EF985934-5DB0-4F18-9809-CFC52C5CB8BAQ33820414-C6D254ED-85C7-4433-9F83-9DD04C4E67CBQ33825634-D10281B2-41B3-4570-B207-E3BE69B1DED8Q34243590-80B7225B-61A8-4C9A-B9A7-9C68974780A7Q34491552-515DD87A-4DAB-4A9D-B9C8-811233E3FE93Q34515243-FC4EA980-9CBA-447B-AB48-E1D762E533B0Q34956792-65BA5AE7-33B7-4012-BE2A-F3971CE6C0BBQ35273711-2A6696C9-FAA4-47F4-A7CA-6B235A5AC0CFQ35917770-EFF05DFA-9658-4AB3-89BE-940FF349C233Q35918209-30E37EDB-CD86-440A-BE4B-082398D8F38FQ36061478-397A5754-B785-46B7-ADFB-E263CBCCBA2AQ36688818-247D7306-E0C1-4D1B-9293-1E86370415DCQ36881585-82584BA5-1EF8-4F00-8AF4-19D861F02B20Q36968540-68E7C87E-C467-421E-B6E3-CFF18F4A0568Q36980425-AA983EB4-05C1-46CE-B25A-5D56CEBE2B46Q37026521-4A8A4186-1A25-4172-B33C-FDBF2DED41A1Q37161460-56C172FD-D62F-46DA-ACF4-3EF5146BF4FFQ37608274-13927BFC-1BE4-4534-837C-2B066AE423A3Q37637169-8628EA5E-CA28-4808-A9CF-EE28C9DD6D22Q38042719-43809C7D-FF08-499B-8146-E3D276289774Q38604855-2B02E28E-BB05-42FE-8D7E-E4AE3BC3020CQ38605085-3B2B062E-D163-4F87-BB14-B5D91831571FQ38627088-F7954DF9-71AA-48EE-9BF2-4C586ACBB50BQ38652042-780E7A86-B92D-405D-973F-33728E339193Q38763542-8999857E-0793-4D91-8761-1201DEDCF7AFQ38779519-43A13204-EA19-4B71-9568-320E1B762BA6Q40226374-1FBE8A50-1074-4FDB-96BD-A6710348050AQ40252432-D41C0027-7A18-4336-B819-8ACF3387277BQ40440920-D72EFA04-42B3-4F53-9CAC-C0F4B2651B30Q40926645-E976A289-226D-4042-A8DF-97DBD58ED32DQ41695599-788A19F3-C443-4711-9671-B20BAF858956Q42089409-5848B681-FCB2-4123-B5B4-80C6DEAA9744Q42234991-3AED57C7-1935-49D8-A472-53C01D1FA8C0Q42529898-7968882F-2649-4018-AF2E-08064B46497AQ43880447-E7D28ECE-8625-4ACC-9925-69CCBACD93F4Q47097212-2913D37E-9C36-4F7F-A701-3E7219B59F0AQ47119843-3DB8A037-B4CB-46E8-8FEC-D442B35912C8
P2860
Achromobacter xylosoxidans in cystic fibrosis: prevalence and clinical relevance.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年学术文章
@wuu
2006年学术文章
@zh
2006年学术文章
@zh-cn
2006年学术文章
@zh-hans
2006年学术文章
@zh-my
2006年学术文章
@zh-sg
2006年學術文章
@yue
2006年學術文章
@zh-hant
name
Achromobacter xylosoxidans in cystic fibrosis: prevalence and clinical relevance.
@en
Achromobacter xylosoxidans in cystic fibrosis: prevalence and clinical relevance.
@nl
type
label
Achromobacter xylosoxidans in cystic fibrosis: prevalence and clinical relevance.
@en
Achromobacter xylosoxidans in cystic fibrosis: prevalence and clinical relevance.
@nl
prefLabel
Achromobacter xylosoxidans in cystic fibrosis: prevalence and clinical relevance.
@en
Achromobacter xylosoxidans in cystic fibrosis: prevalence and clinical relevance.
@nl
P2093
P1476
Achromobacter xylosoxidans in cystic fibrosis: prevalence and clinical relevance.
@en
P2093
Filomeen Haerynck
Frans De Baets
Petra Schelstraete
Sabine Van Daele
P356
10.1016/J.JCF.2006.05.011
P577
2006-06-21T00:00:00Z